Over the last few years, an extensive research has improved our understanding of tumor immunology and enabled the development of novel treatments that can harness the patient’s immune system and prevent immune escape.

Through numerous clinical trials and real-world experience, a large amount of evidence of the potential for long-term survival with immunotherapy agents has been accumulated in various types of malignancy, starting from melanoma to extend to other tumors.

The results of these studies have also highlighted a number of recurring observations with immuno-oncology agents, including their potential for clinical application across a broad patient population and for both conventional and unconventional response patterns.

The clinical success of immune checkpoint blockade with anti-cytotoxic T-lymphocyte-associated antigen (CTLA)-4 and anti-programmed death (PD)-1/PD-ligand (L)1 inhibitor in melanoma and other cancers has encouraged increasing development of other immunotherapies, particularly monoclonal antibodies with other immune targets, adoptive cell transfer and vaccines. It has been estimated that there are over 3000 immuno-oncology trials ongoing, targeting hundreds of disease and immune pathways. Study results have highlighted a number of recurring observations, including the immunotherapy potential for clinical application across a broad patient population and for both conventional and unconventional response patterns.

The successes of the immune-oncology is strongly correlated with the immune system ability of “memory” and adaptability, to improve the time of survival and without selecting resistant form of tumoral cells. Another advantage is that the efficacy of immunotherapy drugs does not seem to be particularly influenced by histology and mutations.

First session of the congress will be jointly organized with the Society for ImmunoTherapy of Cancer (SITC).

Hence, the state of the art of immunotherapy from the clinical point of view in various types of malignances will be exhaustively discussed (lung, head and neck, ovarian, breast, gastrointestinal tract and lymphomas) and on targeting cancer through stimulation of innate immunity with intratumorals.

Then the “Great Debate” sessions, where counterpoint views from leading experts on specific controversial clinical issues will be presented and discussed from different points of view.

Conclusions will be drawn after the last session on Neo-Adjuvant therapies in different types of cancer.

RESPONSABILE SCIENTIFICO

Prof. PAOLO A. ASCIERTO - Direttore Dipartimento Oncologia Medica Melanoma, Immunoterapia Oncologica e Terapie Innovative, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, Napoli

Questo evento sarà accreditato per le seguenti professioni:

BIOLOGO

FARMACISTA - Farmacia Ospedaliera, Farmacia Territoriale

INFERMIERE

MEDICO CHIRURGO - Allergologia e Immunologia Clinica, Anatomia Patologica, Chirurgia Generale, Chirurgia Plastica e Ricostruttiva, Cure Palliative, Dermatologia e Venereologia, Ematologia, Epidemiologia e Sanità Pubblica, Farmacologia e Tossicologia Clinica, Gastroenterologia, Genetica Medica, Ginecologia e Ostetricia, Igiene, Laboratorio Di Genetica Medica, Malattie dell’apparato respiratorio, Medicina Generale, Medicina Interna, Medicina Nucleare, Nefrologia, Neurologia, Oncologia, Patologia Clinica, Radioterapia, Radiodiagnostica, Scienza dell’alimentazione e Dietetica, Urologia

Per iscriversi si prega di contattare la Segreteria all'indirizzo rigamonti@3psolution.it

For any technical issue please contact our website Help desk service at help@3psolution.it